Compare Adaptive Biotechnologies Corp (ADPT) vs Enovix Corporation (ENVX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Enovix Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $25.15 (market cap $4.04B), while Enovix Corporation trades at $4.85 (market cap $1.06B). The key difference: Adaptive Biotechnologies Corp is far larger — about 3.8× Enovix Corporation's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals.
| ADPT | ENVX | |
|---|---|---|
Market Cap | $4.04B | $1.06B |
Sector | Health | Technology |
52-Week High | $25.45 | $13.19 |
52-Week Low | $12.30 | $3.68 |
Enterprise Value | $4.10B | $1.07B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
ENVX trades at $4.92, up 6.03% in the last 24 hours, with a bullish technical signal despite negative profitability. Recent earnings beats and the appointment of a former Apple executive as COO highlight operational progress. The stock shows strong analyst support with a consensus price target of $12.38, though cash flow remains negative as the company scales production.
Outlook is cautiously optimistic given high growth potential in advanced battery technology, but significant execution risks and persistent losses require careful monitoring. The stock offers upside if production ramps successfully, but volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →
